Junda Kui (均达奎)均达奎
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 上海新亚药业有限公司Chinese legal name: 上海新亚药业有限公司
主要成分Active Ingredients
- 川芎嗪Chuanqiong Qin
药物知识说明
川芎嗪是一种在国家药监局注册认定的药品。该药品含有川芎嗪-d2a41f6f等成分。
该药品关联的活性成分包括：川芎嗪Chuanqiong Qin。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：上海新亚药业有限公司Chinese legal name: 上海新亚药业有限公司。
您可以探索含有相同成分的其他药品：川芎嗪-d2a41f6f成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 均达奎) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 川芎嗪Chuanqiong Qin.
Manufacturers recorded for this product: 上海新亚药业有限公司Chinese legal name: 上海新亚药业有限公司.
Explore other medicines containing the same ingredient: 川芎嗪 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 均达奎Recorded Chinese name: 均达奎
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 0.1g0.1 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 上海新亚药业有限公司Chinese legal name: 上海新亚药业有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20041066
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20041066
Manufacturer
Chinese legal name: 上海新亚药业有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20041066
生产企业
上海新亚药业有限公司(国产)
适应症
本品用于缺血性脑血管疾病（如脑供血不足、脑血栓形成、脑栓塞）。
用法用量
静脉滴注。一次50～100mg，缓慢滴注，宜在3～4小时滴完，一日1次，10～15天为一疗程或遵医嘱。
不良反应
偶见胃部不适、口干、嗜睡，减量可缓解，过敏反应可见。
禁忌
1.对本品过敏者禁用。|2.脑出血或有出血倾向的患者禁用。
注意事项
1.脑水肿或少量出血者与缺血性脑血管病鉴别困难时应慎用。|2.对冠心病患者在静脉滴注时应注意观察心率、血压的变化。|3.血压低者慎用。|4.本品静脉滴注速度不宜过快，应严格控制静滴速度。|5.本品为含钠制剂，高钠者应用时请注意。|6.使用本品要密切观察，一旦发生过敏反应，立即停药迅速采取地塞米松、扑尔敏等抗过敏药物救治。|7.使用前请详细检查，如有药液浑浊或异物、瓶身破裂、封口松动等，请勿使用，以策安全。|8.本品一经使用，即有空气进入，剩余药液切勿贮存使用。
贮藏
遮光，密闭保存
规格
0.1g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.